Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
about
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.New developments in the management of Waldenström macroglobulinemiaDexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.Waldenstrom's Macroglobulinemia: An Update.Ibrutinib therapy for lymphoplasmacytic lymphoma.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Waldenström macroglobulinemia treatment algorithm 2018.Ibrutinib for rituximab-refractory Waldenström macro-globulinemia.Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs
P2860
Q33798887-398D6EF1-2566-4F01-BCAF-9A9E03A1879AQ34553880-61319183-57B0-4DF2-A9D6-49CBA6D7710FQ38635212-B4110D98-4334-4229-8691-1F084190ED4AQ38665207-10C9F5D8-A515-46A9-AEFF-2E2D611C598DQ38693304-5706DDA1-D1E6-4F36-ABBB-0BED667E8AE8Q39375290-4020FFE3-D8A5-4AB7-9D2C-05D30317F41FQ47134329-0DA9A629-7E20-4EB7-95A4-A38B96D4F59CQ47142533-1A24C66A-4ABC-4AAD-ABC2-765789DDA090Q47736653-E9C083D2-9CF3-4F3B-80C0-2FF57C77A795Q48097492-4D44525D-6B79-4488-86E4-1151FE2535C4Q49226138-A6853019-AAC4-418A-894F-10E5A3F65E9BQ50065065-1315C1B1-C1F5-48CB-B868-0663BA00FFF1Q50121608-9B213F7C-A8A3-46E4-A3E7-1A11F8FE3AEDQ55018872-307D0AA2-E742-489E-ABA8-9B2A3D5E6F14Q55359715-425B9454-B6C0-49B1-91D0-8971E16495BCQ55690832-0936581B-01CC-43B9-9506-D38CFFB20CCEQ58701117-80075D71-9F32-432A-B5C2-E89839F930DB
P2860
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@ast
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@en
type
label
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@ast
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@en
prefLabel
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@ast
Ibrutinib for patients with ri ...... l, multicentre, phase 3 trial.
@en
P2093
P50
P1433
P1476
Ibrutinib for patients with ri ...... al, multicentre, phase 3 trial
@en
P2093
Alessandra Tedeschi
Carlos Fernández de Larrea
Chaim Shustik
Christian Buske
David Macdonald
Elizabeth Bilotti
Jeffrey V Matous
Jianling Li
Leonard T Heffner
Marie-Christine Kyrtsonis
P304
P356
10.1016/S1470-2045(16)30632-5
P50
P577
2016-12-10T00:00:00Z